Frederick W. Miller

Frederick W. Miller's AcademicInfluence.com Rankings

Frederick W. Miller

Computer Science

#10175

World Rank

#10671

Historical Rank

Computational Linguistics

#2568

World Rank

#2593

Historical Rank

Machine Learning

#4654

World Rank

#4706

Historical Rank

Artificial Intelligence

#5015

World Rank

#5080

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Frederick W. Miller's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Frederick W. Miller Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Frederick W. Miller's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A New Approach to the Classification of Idiopathic Inflammatory Myopathy: Myositis‐Specific Autoantibodies Define Useful Homogeneous Patient Groups (1991) (914)
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. (2010) (614)
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups (2017) (524)
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups (2017) (500)
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. (2013) (489)
A novel autoantibody to a 155-kd protein is associated with dermatomyositis. (2006) (451)
Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. (2012) (331)
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. (2001) (289)
Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. (1992) (287)
Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. (1989) (283)
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. (2006) (282)
Antibody to signal recognition particle in polymyositis. (1990) (277)
Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. (1993) (271)
Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. (2012) (270)
Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report (2006) (261)
Classification criteria for the idiopathic inflammatory myopathies. (1997) (243)
Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. (2014) (228)
International consensus on preliminary definitions of improvement in adult and juvenile myositis. (2004) (218)
The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies (2013) (211)
Predictors of Clinical Improvement in Rituximab‐Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis (2014) (210)
Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies (2000) (180)
Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. (2004) (174)
Age-related somatic structural changes in the nuclear genome of human blood cells. (2012) (168)
Defining Clinical Improvement in Adult and Juvenile Myositis. (2003) (166)
Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. (1998) (165)
Polymyositis: An overdiagnosed entity (2004) (165)
Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. (2003) (164)
Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies: Distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 Allelic Profiles Distinguish European American Patients With Different Myositis Autoantibodies (2006) (162)
Myositis: Immunologic Contributions to Understanding Cause, Pathogenesis, and Therapy (1995) (157)
Magnetic resonance imaging in the idiopathic inflammatory myopathies. (1991) (152)
International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. (2005) (147)
Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. (1997) (146)
Occupational exposures and autoimmune diseases. (2002) (144)
The role of genetic factors in autoimmune disease: implications for environmental research. (1999) (141)
The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies (2013) (139)
Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle (1992) (137)
Classification and treatment of the juvenile idiopathic inflammatory myopathies. (1997) (137)
Idiopathic inflammatory myopathies (2002) (136)
The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. (1990) (135)
Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. (1993) (135)
Diagnosis and classification of idiopathic inflammatory myopathies (2016) (129)
Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. (2011) (128)
Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity (2008) (128)
Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. (2001) (126)
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments (1997) (124)
Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. (2009) (123)
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. (2013) (122)
Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. (1995) (122)
EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report (2017) (122)
Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. (2000) (119)
Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus. (1987) (117)
Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups (2015) (116)
Criteria for environmentally associated autoimmune diseases. (2012) (114)
Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. (1990) (112)
Increasing Prevalence of Antinuclear Antibodies in the United States (2020) (109)
Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. (2002) (108)
Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes (2015) (105)
Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies: Distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 Allelic Profiles and Motifs Define Clinicopathologic Groups in Caucasians (2005) (105)
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials (2013) (104)
Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. (2009) (104)
Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. (1992) (101)
Myositis-specific autoantibodies. Touchstones for understanding the inflammatory myopathies. (1993) (98)
Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. (2009) (98)
Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. (2010) (96)
Update on the genetics of the idiopathic inflammatory myopathies. (2000) (94)
Predominant TCR-alpha beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. (1994) (94)
Approaches for identifying and defining environmentally associated rheumatic disorders. (2000) (92)
A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. (1994) (91)
Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. (1998) (87)
Mechanisms of Disease: environmental factors in the pathogenesis of rheumatic disease (2007) (86)
Risk factors and disease mechanisms in myositis (2018) (85)
Expert Panel Workshop Consensus Statement on the Role of the Environment in the Development of Autoimmune Disease (2014) (82)
Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. (2008) (82)
HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. (2006) (81)
Polymorphisms in the IL‐1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies (2000) (79)
Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis (2019) (77)
Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. (2006) (77)
Identification of distinctive interferon gene signatures in different types of myositis (2019) (76)
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative In (2017) (75)
Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. (1998) (73)
Endothelial cell activation and neovascularization are prominent in dermatomyositis (2006) (73)
The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. (1989) (72)
Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. (2015) (70)
Diagnostic criteria for polymyositis and dermatomyositis (2003) (66)
Early Illness Features Associated With Mortality in the Juvenile Idiopathic Inflammatory Myopathies (2014) (65)
Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. (1999) (64)
New approaches to the assessment and treatment of the idiopathic inflammatory myopathies (2012) (63)
Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. (2007) (62)
Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups (2019) (61)
UV Radiation Regulates Mi-2 through Protein Translation and Stability* (2008) (61)
Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. (2011) (58)
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis (2017) (57)
NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. (1995) (56)
Laboratory evaluation of the inflammatory myopathies (1995) (56)
Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. (2001) (55)
Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. (2013) (55)
The natural history of encephalomyocarditis virus-induced myositis and myocarditis in mice. Viral persistence demonstrated by in situ hybridization (1988) (54)
Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. (2009) (54)
Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. (2005) (53)
Possible roles and determinants of microchimerism in autoimmune and other disorders. (2004) (53)
A 5' splice junction mutation leading to exon deletion in an Ashkenazic Jewish family with phosphofructokinase deficiency (Tarui disease). (1993) (52)
Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages (2006) (51)
Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups (2012) (49)
Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. (2008) (48)
Molecular detection of persistent Borrelia burgdorferi in a man with dermatomyositis. (1992) (47)
Idiopathic inflammatory muscle disease: clinical aspects. (2000) (46)
Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. (2007) (46)
Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis (2020) (46)
Association of Anti–3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients (2017) (45)
Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups (1990) (44)
The Association of Arsenic Exposure and Metabolism With Type 1 and Type 2 Diabetes in Youth: The SEARCH Case-Control Study (2016) (44)
The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. (2007) (44)
Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. (2004) (43)
Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases (2011) (43)
Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. (2008) (43)
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. (1997) (43)
A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. (2017) (42)
Abnormal profile of serum proteinase inhibitors in cancer patients. (1984) (42)
HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. (2009) (40)
Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies (2010) (40)
Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging. (1998) (40)
Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood (2012) (40)
Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. (2002) (39)
Environmental agents and autoimmune diseases. (2011) (38)
Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis (2015) (38)
Environmental factors associated with disease flare in juvenile and adult dermatomyositis (2017) (38)
Novel gastrointestinal tract manifestations in juvenile dermatomyositis. (1999) (38)
Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. (2020) (37)
State of the art: what we know about infectious agents and myositis (2011) (37)
Accommodating measurements below a limit of detection: a novel application of Cox regression. (2014) (36)
Familial autoimmunity and the idiopathic inflammatory myopathies (2000) (36)
Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies (2009) (36)
The αβ T-Cell Receptor Repertoire in Inclusion Body Myositis: Diverse Patterns of Gene Expression by Muscle-infiltrating Lymphocytes (1994) (35)
Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. (2008) (35)
Epitope mapping of the cloned human autoantigen, histidyl-tRNA synthetase. Analysis of the myositis-associated anti-Jo-1 autoimmune response. (1989) (35)
Viral and host genetic factors influence encephalomyocarditis virus-induced polymyositis in adult mice. (1987) (35)
HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. (2003) (35)
Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. (2005) (35)
Noninfectious environmental agents associated with myopathies. (1993) (35)
An enzyme-linked immunosorbent assay for the detection and quantitation of anti-Jo-1 antibody in human serum. (1987) (33)
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis (2017) (33)
Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis (2015) (31)
Mass spectrometric determination of IgG subclass-specific glycosylation profiles in siblings discordant for myositis syndromes. (2011) (29)
Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. (2009) (27)
Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis (2018) (27)
A novel gene oriented in a head-to-head configuration with the human histidyl-tRNA synthetase (HRS) gene encodes an mRNA that predicts a polypeptide homologous to HRS. (1995) (27)
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria—methodological aspects (2017) (25)
The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. (2018) (25)
Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. (2004) (25)
Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. (2014) (24)
Genetic risk and protective factors for the idiopathic inflammatory myopathies (2009) (24)
Associations Between Selected Xenobiotics and Antinuclear Antibodies in the National Health and Nutrition Examination Survey, 1999–2004 (2015) (24)
Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies (2014) (23)
Metabolic abnormalities and cardiovascular risk factors in children with myositis. (2009) (23)
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Co (2017) (23)
Reproductive and Hormonal Risk Factors for Antinuclear Antibodies (ANA) in a Representative Sample of U.S. Women (2014) (23)
Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies (2020) (23)
Humoral immunity and immunogenetics in the idiopathic inflammatory myopathies (1991) (23)
Chapter 26 – Juvenile Dermatomyositis (2016) (22)
Nifedipine in the treatment of migraine headache and amaurosis fugax in patients with systemic lupus erythematosus. (1984) (21)
CD3Z hypermethylation is associated with severe clinical manifestations in systemic lupus erythematosus and reduces CD3&zgr;-chain expression in T cells (2016) (21)
Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis (2014) (19)
Predictors of Reduced Health‐Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies (2017) (19)
Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research (2014) (18)
A47: Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies (2014) (17)
Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases* (2011) (16)
The ribosomes of Plasmodium berghei: isolation and ribosomal ribonucleic acid analysis (1978) (16)
Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis (2018) (15)
A Consensus Hybrid Definition Using a Conjoint Analysis Is the Proposed As Response Criteria for Minimal and Moderate Improvement for Adult Polymyositis and Dermatomyositis Clincal Trials. (2014) (15)
Autoantibodies as Predictive and Diagnostic Markers of Idiopathic Inflammatory Myopathies (2004) (15)
Spontaneously proliferating human B lymphocytes make autoantibodies. (1988) (15)
Long-term outcomes in Juvenile Myositis patients. (2020) (15)
Classification and prognosis of inflammatory muscle disease. (1994) (15)
Thyroid stimulating and thyrotrophin binding-inhibitory immunoglobulin activity in patients with systemic lupus erythematosus having thyroid function abnormalities. (1991) (15)
Genome-Wide Association Study of Dermatomyositis Reveals Shared Genetic Risk Factors with Other Autoimmune Diseases (2011) (14)
Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. (2020) (14)
Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies (2014) (14)
Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy (2013) (14)
T cell‐mediated immune mechanisms in myositis (1995) (13)
Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. (2016) (13)
Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms. (2009) (13)
Medications received by patients with juvenile dermatomyositis. (2018) (13)
Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis (2019) (12)
The future status of pediatric rheumatology in the United States: strategic planning for the year 2000. American College of Rheumatology Blue Ribbon Committee for Academic Pediatric Rheumatology. (2000) (12)
Focal myositis presenting as pseudothrombophlebitis of the neck in a patient with mixed connective tissue disease. (1996) (12)
Genomic organization, transcriptional mapping, and evolutionary implications of the human bi-directional histidyl-tRNA synthetase locus (HARS/HARSL). (2002) (12)
Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry (2020) (11)
The alpha beta T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. (1994) (11)
Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus (2017) (11)
Defining anti-synthetase syndrome: a systematic literature review. (2022) (11)
Polymyositis/dermatomyositis associated with dermatitis herpetiformis. (1989) (11)
Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases (2015) (10)
Classification of Idiopathic Inflammatory Myopathies (2009) (10)
New perspectives on the idiopathic inflammatory myopathies of childhood (1994) (10)
Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families, and Healthcare Providers (2007) (10)
γδ T cell receptor gene expression by muscle‐infiltrating lymphocytes in the idiopathic inflammatory myopathies (1995) (9)
HLA-DRB1 allelic epitopes that associate with autoimmune disease risk or protection activate reciprocal macrophage polarization (2021) (9)
Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a case–control study (2007) (8)
Xenotropic murine leukemia virus-related virus is not associated with chronic fatigue syndrome in patients from different areas of the us in the 1990s (2011) (8)
Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960–2014 (2020) (8)
Restricted and shared patterns of TCR beta-chain gene expression in silicone breast implant capsules and remote sites of tissue inflammation. (2000) (8)
Genetics of autoimmune diseases. (1995) (8)
Abnormalities of the immune system in the idiopathic inflammatory myopathies. (1988) (8)
Prescription medication use and antinuclear antibodies in the United States, 1999-2004. (2018) (8)
Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis (2021) (7)
Transethnic associations among immune-mediated diseases and single-nucleotide polymorphisms of the aryl hydrocarbon response gene ARNT and the PTPN22 immune regulatory gene. (2019) (7)
Increasing Prevalence of Antinuclear Antibodies in the United States (2022) (7)
Baseline Factors Associated with Self-reported Disease Flares Following COVID-19 Vaccination among Adults with Systemic Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. (2022) (7)
Developing international consensus on measures of improvement for patients with myositis (2007) (7)
Influence of 9-beta-D-arabinofuranosyladenine on total protein synthesis and on differential gene expression of unique proteins in the rodent malarial parasite Plasmodium berghei. (1977) (7)
Urinary cancer-related protein EDC1 and serum inter-alpha trypsin inhibitor in breast cancer. (1984) (7)
Food Biotechnology: Can You Afford to Be Left Out? (1997) (6)
Noninfectious Environmental Agents and Autoimmunity (2020) (6)
An efficient method for enrichment of histidyl-tRNA synthetase (Jo-1 antigen) from HeLa cells. (1987) (6)
Antinuclear antibodies and mortality in the National Health and Nutrition Examination Survey (1999-2004) (2017) (5)
Progress report on the development of new classification criteria for adult and juvenile idiopathic inflammatory myopathies (2013) (5)
Helicobacter pylori seropositivity is associated with antinuclear antibodies in US adults, NHANES 1999–2000 (2020) (5)
Idiopathic inflammatory myopathies: dermatomyositis, polymyositis, and related disorders in the child and adult (1994) (5)
Successful Prevention of an Anaphylactoid Reaction to High-Dose Methotrexate (1989) (5)
HLA-A, -B, -Cw, -DQA1 and -DRB1 alleles in a Caucasian population from Bethesda, USA (2004) (5)
Chimeric cells of maternal origin do not appear to be pathogenic in the juvenile idiopathic inflammatory myopathies or muscular dystrophy (2015) (5)
47XXY and 47XXX in Scleroderma and Myositis (2022) (5)
Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies. (2020) (5)
Gamma delta T cell receptor gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. (1995) (4)
The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. (2022) (4)
In vitro response of peripheral blood lymphocytes from patients with rheumatoid arthritis to lipopolysaccharides. (1980) (4)
A58: Demographics, Clinical Features and Therapies of Patients with Juvenile Dermatomyositis Participating in a National Myositis Patient Registry (2014) (4)
277 – Polymyositis and Dermatomyositis (2012) (4)
OP0035 Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies (2013) (4)
American College of Rheumatology / European League Against Rheumatism Criteria for Minimal , Moderate , and Major Clinical Response in Adult Dermatomyositis and Polymyositis (2017) (4)
Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface? (2010) (4)
Myositis and myopathies. (1996) (3)
Environmental Influences on Autoimmunity and Autoimmune Diseases (2006) (3)
Anti-Jo-1 Antibodies are Directed at an Evolutionarily-Conserved, Conformational Site on Human Histidyl-tRNA Synthetase (1989) (3)
Anti‐Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis (2021) (3)
CHAPTER 23 – Noninfectious Environmental Agents and Autoimmunity (2006) (3)
Vasculitis in the Idiopathic Inflammatory Myopathies (2012) (3)
The lupus susceptibility allele DRB1*03:01 encodes a disease-driving epitope (2022) (3)
Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies (2022) (2)
Theroleofanautoantigen, histidyl-tRNA synthetase, inthe induction andmaintenance ofautoimmunity (1990) (2)
Signal Recognition Particle Autoantibodies (1996) (2)
Development of disease activity and damage indices for myositis: Further testing of four tools in adult onset patients. (2002) (2)
Dense Genotyping of Immune-Related Loci in the Idiopathic Inflammatory Myopathies Confirms HLA alleles as strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Annals of the Rheumatic Diseases. (2015) (2)
Idiopathic anasarca associated with oligoclonal gammopathy in systemic lupus erythematosus. (1987) (2)
Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: comment on the article by Ruperto et al. (2008) (2)
HLA-A, -B, -Cw, -DQA1 and DRB1 in an African American population from Bethesda, USA (2004) (2)
Post-Zygotic and Inter-Individual Structural Genetic Variation in a Presumptive Enhancer Element of the Locus between the IL10Rβ and IFNAR1 Genes (2013) (2)
Latitudinal gradients in the relative prevalence of dermatomyositis and its associated autoantibody, anti-Mi-2, in idiopathic inflammatory myopathy (1996) (2)
Autoantibody Production by Human B Lymphocytes which Spontaneously Proliferate (1987) (2)
Is occupational exposure to mineral oil a risk factor for rheumatoid arthritis? (2006) (2)
The role of an autoantigen , histidyltRNA histidyltRNA histidyltRNA synthetase , in the induction and maintenance of autoimmunity (1)
Association with HLA-DRβ1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis (2022) (1)
Myositis and myopathies. (1996) (1)
Genome-wide imputation identifies novel associations and localises signals in idiopathic inflammatory myopathies. (2022) (1)
Use of the Open ROBOKOP Knowledge Graph-Based Application to Provide Mechanistic Explanations for Observed Associations between Environmental Exposures and Immune-Mediated Diseases (2020) (1)
Response to: ‘Correspondence on ‘EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups’’ by Irfan et al (2021) (1)
Evidence for major differences in ribosomal subunit proteins from Plasmodium berghei and rat liver. (1984) (1)
The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). (2022) (1)
Mo1851 POPULATION-BASED ESTIMATES FOR INFLAMMATORY BOWEL DISEASE PREVALENCE: RESULTS FROM THE U.S NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (2020) (1)
A25: The Association of Immunogenetic and Environmental Factors with Disease Course in Patients with Juvenile Idiopathic Inflammatory Myopathies (2014) (1)
Hygiene Hypothesis Indicators and Prevalence of Antinuclear Antibodies in US Adolescents (2022) (1)
The Climate Emergency and the Health of Our Patients: The Role of the Rheumatologist (2022) (1)
Myositis Genetics Consortium. Genome-Wide Association Study of Dermatomyositis Reveals Shared Genetic Risk Factors with Other Autoimmune Diseases (2011) (1)
Alternative Scoring of the Cutaneous Assessment Tool ( CAT ) in Juvenile Dermatomyositis : Results Using an Abbreviated Format (2017) (0)
A novel estrogen receptor 1-sphingomyelin phosphodiesterase acid like 3B pathway mediates rituximab response in myositis patients. (2022) (0)
4M052 MTP: 040 - Adult Inflammatory Myopathy (2018) (0)
Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus (2020) (0)
Correction: 2016 American college of rheumatology/European league against rheumatism criteria for minimal moderate, and major clinical response in juvenile dermatomyositis (2018) (0)
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles. (2023) (0)
The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry (2022) (0)
Slicing and dicing myositis for cures and prevention (2021) (0)
P.21.5 Progress report on the development of new classification criteria for adult and juvenile idiopathic inflammatory myopathies (2013) (0)
The Impact of Cigarette Smoking on the Clinical and Serological Phenotypes of Polymyositis and Dermatomyositis (2018) (0)
150 – Management of inflammatory muscle disease (2015) (0)
Introduction to Myositis (2019) (0)
Age-related accumulation of somatic structural changes in the nuclear genome of human blood cells in vivo (2012) (0)
HLA Alleles Associated with Interstitial Lung Disease in North Americans with Idiopathic Inflammatory Myopathy. (2022) (0)
Expanded assessment of xenobiotic associations with antinuclear antibodies in the United States, 1988-2012. (2022) (0)
Anti-Sp4 autoantibodies co-occur with anti-TIF1 and are associated with distinct clinical features and immunogenetic risk factors in juvenile myositis. (2023) (0)
Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features. (2022) (0)
Axial Pain and Arthritis in Diagnosed Inflammatory Bowel Disease: US National Health and Nutrition Examination Survey Data (2022) (0)
Influence of 9-0D-arabinofuranosyladenine on total protein synthesis and on differential gene expression of unique proteins in the rodent malarial parasite Plasmodium berghei ( isoelectric focusing / lithium dodecyl sulfate / polyacrylamide gel electrophoresis / inhibition by drug ) (0)
Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes (2022) (0)
Outcome assessment in the idiopathic inflammatory myopathies (2018) (0)
Benzophenone-3 and antinuclear antibodies in U.S. adolescents and adults ages 12-39 years (2022) (0)
Table 3 Subgroups of the Idiopathic Inflammatory Myopathies in Adults and Children (2007) (0)
050. International Immunochip Study in the Idiopathic Inflammatory Myopathies Identifies Genetic Differences Between Clinical Subgroups, and Confirms HLA Alleles as Strongest Genetic Risk Factor (2015) (0)
Association of Anti-HSC70 Autoantibodies with Cutaneous Ulceration and Severe Disease in Juvenile Dermatomyositis. (2021) (0)
Antigen Presentation-Independent Reciprocal Immune Modulation by HLA-DRB1 Allelic Epitopes that Associate with Autoimmune Disease Risk or Protection (2020) (0)
Animal models of myositis. (1988) (0)
On Determining the Effects of Therapy on Disease Damage in Non Randomized Studies with Multiple Treatments: A Study of Juvenile Myositis (2009) (0)
182. Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies (2014) (0)
Clinical Presentation and Therapy of Idiopathic Inflammatory Myopathies (2004) (0)
Association of distance to swine concentrated animal feeding operations with immune-mediated diseases: An exploratory gene-environment study. (2022) (0)
Benzophenone-3 and prevalence of antinuclear antibodies in adolescents and adults ages 12-39 in the U.S. population (2020) (0)
discordance in systemic lupus erythematosus Changes in the pattern of DNA methylation associate with twin Material Supplemental (2009) (0)
International immunochip study in the idiopathic inflammatory myopathies identifies novel susceptability loci and confirms HLA as strongest genetic risk factor (2014) (0)
Response to: ‘Comment on: ‘Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis’ by Sabbagh S et al’ by Yang et al (2019) (0)
Performance of the 2016 ACR-EULAR myositis response criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles. (2023) (0)
US Inflammatory Bowel Disease Prevalence: Surveillance Data from the U.S. National Health and Nutrition Examination Survey (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Frederick W. Miller?

Frederick W. Miller is affiliated with the following schools:

Frederick W. Miller's Academic­Influence.com Rankings

Frederick W. Miller's Degrees

Similar Degrees You Can Earn

Why Is Frederick W. Miller Influential?

Frederick W. Miller's Published Works

Published Works

What Schools Are Affiliated With Frederick W. Miller?

Frederick W. Miller's AcademicInfluence.com Rankings